Preparation of celecoxib solid dispersions for dermal application: in vitro characterization and skin irritation test

The purpose of this work was to improve the dissolution and skin permeability characterestics of celecoxib. Solid dispersions (SDs) of celecoxib were prepared using PEG 4000, PVP K30 and HPβCD by the kneading method. The dispersions were characterized by, (DSC), (XRD) and in vitro drug dissolution....

Full description

Saved in:
Bibliographic Details
Published in:Journal of drug delivery science and technology 2011, Vol.21 (6), p.509-516
Main Authors: Soliman, S.M., Abdel Malak, N.S., El Gazayerly, O.N., Abdel Rehim, A.A.
Format: Article
Language:English
Subjects:
Anti-inflammatory effect
Biological and medical sciences
Celecoxib
General pharmacology
Histopathology
Medical sciences
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Skin permeation
Solid dispersions
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this work was to improve the dissolution and skin permeability characterestics of celecoxib. Solid dispersions (SDs) of celecoxib were prepared using PEG 4000, PVP K30 and HPβCD by the kneading method. The dispersions were characterized by, (DSC), (XRD) and in vitro drug dissolution. The solubility and dissolution of SDs were markedly increased as compared to plain drug. The kneaded dispersions showing high dissolution were incorporated in an o/w cream and evaluated for in vitro drug permeation through rabbit skin. The permeation rate of celecoxib were significantly increased in the case of SDs when compared to plain drug. The anti-inflammatory effect of celecoxib-PVP K30 cream was more effective in inhibiting rat paw edema when compared to celecoxib cream. Skin irritancy and histopathological investigation of rat skin revealed its safety thus confirming the advantage of improved pharmacological activity and safety of celecoxib when administered topically as solid dispersion with PVPK30.
ISSN:1773-2247
DOI:10.1016/S1773-2247(11)50082-6